News & Updates

People who inject drugs (PWID) and are receiving treatment for hepatitis C virus (HCV) show a substantial decline in liver disease and mortality, according to a study.

There are currently 40 approved vaccines against COVID-19, of which 11 have been granted Emergency Use Authorization by the World Health Organization. [covid19.trackvaccines.org/vaccines/approved] With over 300 other candidates in the development pipeline – over 100 of which are in clinical testing [vac-lshtm.shinyapps.io/ncov_vaccine_landscape] – are new vaccines necessary?

A novel nitric oxide-releasing gel, berdazimer 10.3%, proves effective in the treatment of patients with water warts or molluscum contagiosum skin infection, facilitating clearance of lesions with low adverse event rates, as shown in the phase III B-SIMPLE4 trial.

COVID-19 appears to alter the menstrual cycle and impair mental health in women hospitalized for the disease, a recent study has found.

Cases of acute, severe hepatitis of unknown aetiology in young children have increased recently and investigations are underway, says an expert during a media briefing at ILC 2022.

In the treatment of COVID-19 inpatients, intravenous administration of dexamethasone leads to a shorter hospital stay compared with methylprednisolone, according to a study.

Both resolved and chronic infections of hepatitis C virus (HCV) lead to a higher risk of developing kidney disease, a recent study has found. This effect is further pronounced in genotype 1 HCV.

Treatment with intravenous or oral solithromycin is well-tolerated and leads to clinical improvement in most children and adolescents with community-acquired bacterial pneumonia (CABP), results of a recent study have shown.

The serine protease inhibitor camostat mesylate does not appear to be an effective antiviral agent in patients with early-phase COVID-19, having failed to stop SARS-CoV-2 in its tracks in a phase II trial.